Return on Assets (ROA): Neurocrine Biosciences's financial strength is reflected in its exceptional ROA, which exceeds ...

Corient Private Wealth LLC grew its stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 64.0% during the ...

Envestnet Portfolio Solutions Inc. boosted its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) ...

To make the world smarter, happier, and richer. Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches ...

We recently compiled a list of the 15 Best Biotech Stocks to Buy According to Billionaires. In this article, we are going to ...

JPMorgan raised the firm’s price target on Neurocrine (NBIX) to $184 from $183 and keeps an Overweight rating on the shares after surveying 24 ...

Of the 103 patients who completed the Phase III trial, more than half witnessed remission from a drug-induced condition that ...

Highlights,A substantial portion of Neurocrine Biosciences' shares is currently held by institutional entities.,Avantax ...

Over the last 7 days, the United States market has risen by 1.8%, contributing to a 10% increase over the past year, with earnings projected to grow by 14% annually in the coming years. In this ...

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Neurocrine Biosciences wasn’t one of them. The 10 stocks that made the ...

14 analysts have expressed a variety of opinions on Neurocrine Biosciences (NASDAQ:NBIX) over the past quarter, offering a diverse set of opinions from bullish to bearish. The following table ...

Neurocrine Biosciences’ Kinect 4 open-label study (NCT02405091) found that 59.2% of patients achieved remission of tardive dyskinesia through once-daily doses of Ingrezza (valbenazine).